Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide and Bisphosphonates in Smoldering/Indolent Myeloma
NCT00083382Phase 2Completed
- Sponsor
- University of Arkansas
- Start
- Dec 1998
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in smoldering multiple myeloma (SMM) and multiple myeloma (MM), sponsored by University of Arkansas. Primary endpoint: Best Response at 2 years. Started Dec 1998; status: completed.
02
Drugs
thalidomide
03
Conditions
smoldering multiple myeloma (SMM)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00083382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083382.